McKenney et al. reported that mutations in epigenetic regulators, including mutations in isocitrate dehydrogenase 1 (IDH1), IDH2, and TET2, were identified in patients who progressed from MPN to AML [104,105]. Here, TET2 is linked to myeloproliferative neoplasm.